Bio-Rad Laboratories Inc (BIO)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 2,566,525 | 2,580,209 | 2,562,604 | 2,605,238 | 2,671,262 | 2,720,366 | 2,769,042 | 2,779,031 | 2,802,249 | 2,804,730 | 2,870,979 | 2,895,811 | 2,922,545 | 2,979,615 | 2,879,829 | 2,700,778 | 2,545,626 | 2,380,215 | 2,293,585 | 2,329,324 |
Total current assets | US$ in thousands | 3,030,300 | 3,055,620 | 3,056,250 | 3,060,940 | 3,048,330 | 3,146,770 | 3,138,870 | 3,277,250 | 3,157,980 | 3,140,160 | 3,249,700 | 3,303,420 | 1,989,090 | 2,466,290 | 2,289,090 | 2,175,320 | 2,139,840 | 2,323,860 | 2,132,580 | 2,082,590 |
Total current liabilities | US$ in thousands | 467,800 | 497,943 | 486,961 | 466,154 | 522,799 | 558,176 | 581,982 | 589,623 | 568,708 | 570,677 | 613,714 | 648,331 | 680,938 | 649,916 | 587,052 | 609,892 | 631,536 | 986,657 | 926,895 | 869,254 |
Working capital turnover | 1.00 | 1.01 | 1.00 | 1.00 | 1.06 | 1.05 | 1.08 | 1.03 | 1.08 | 1.09 | 1.09 | 1.09 | 2.23 | 1.64 | 1.69 | 1.73 | 1.69 | 1.78 | 1.90 | 1.92 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $2,566,525K ÷ ($3,030,300K – $467,800K)
= 1.00
Bio-Rad Laboratories Inc's working capital turnover has shown fluctuations over the reported periods. Initially relatively stable around the 1.9 range in 2020, the ratio started to decline gradually, reaching a low of 1.00 by the end of 2024. A working capital turnover of 1.00 indicates that the company generated just enough revenue to cover its working capital in that period.
The decreasing trend in the working capital turnover ratio may suggest inefficiencies in managing the company's working capital, such as slow inventory turnover or difficulty collecting receivables. This could potentially impact the company's liquidity and overall financial health. Further analysis of the reasons behind the declining ratio and potential strategies for improving working capital management may be necessary for Bio-Rad Laboratories Inc to enhance its operational efficiency and financial performance.
Peer comparison
Dec 31, 2024